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Abstract
Patients with Disorders of Sex Development (DSD), especially those with gonadal dysgenesis and hypovirilization are at risk
of developing malignant type II germ cell tumors/cancer (GCC) (seminoma/dysgerminoma and nonseminoma), with either
carcinoma in situ (CIS) or gonadoblastoma (GB) as precursor lesion. In 10–15% of 46,XY gonadal dysgenesis cases (i.e., Swyer
syndrome), SRY mutations, residing in the HMG (High Mobility Group) domain, are found to affect nuclear transport or
binding to and bending of DNA. Frasier syndrome (FS) is characterized by gonadal dysgenesis with a high risk for
development of GB as well as chronic renal failure in early adulthood, and is known to arise from a splice site mutation in
intron 9 of the Wilms’ tumor 1 gene (WT1). Mutations in SRY as well as WT1 can lead to diminished expression and function
of SRY, resulting in sub-optimal SOX9 expression, Sertoli cell formation and subsequent lack of proper testicular
development. Embryonic germ cells residing in this unfavourable micro-environment have an increased risk for malignant
transformation. Here a unique case of a phenotypically normal female (age 22 years) is reported, presenting with primary
amenorrhoea, later diagnosed as hypergonadotropic hypogonadism on the basis of 46,XY gonadal dygenesis with a novel
missense mutation in SRY. Functional in vitro studies showed no convincing protein malfunctioning. Laparoscopic
examination revealed streak ovaries and a normal, but small, uterus. Pathological examination demonstrated bilateral GB
and dysgerminoma, confirmed by immunohistochemistry. Occurrence of a delayed progressive kidney failure (focal
segmental glomerular sclerosis) triggered analysis of WT1, revealing a pathogenic splice–site mutation in intron 9. Analysis
of the SRY gene in an additional five FS cases did not reveal any mutations. The case presented shows the importance of
multi-gene based diagnosis of DSD patients, allowing early diagnosis and treatment, thus preventing putative development
of an invasive cancer.
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Introduction
Disorders of Sex development (DSD) are congenital conditions
of incomplete or disordered gonadal development leading to
discordance between genetic sex, gonadal sex, and phenotypic
sex [1]. DSD occurs with an estimated incidence of 1:5000 [1].
Individuals with an underlying DSD, especially those with
specific Y chromosomal material in their karyotype, have an
increased risk for developing a type II germ cell tumor/cancer
(GCC) [2]. GCCs arise from primordial germ cells (PGC) or
gonocytes and can be subdivided into seminomas/dysgermino-
mas and non-seminomas with carcinoma in situ (CIS) or
gonadoblastoma (GB) as precursor lesions [3–4]. GCC risk
varies, but is estimated to be over 30% in patients with complete
gonadal dysgenesis and is often bilateral [2].
Frasier syndrome (FS), currently classified as 46,XY DSD,
complete gonadal dysgenesis, is characterized by gonadal dysgen-
esis, a high risk for development of a GCC and chronic renal
failure in early adulthood. Usually patients with complete gonadal
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dysgenesis are not diagnosed at birth because of their normal
female appearance of external genitalia. However, these patients
will not develop secondary sex characteristics at pubertal age, and
will generally attend the clinic because of primary amenorrhea,
with hormonal analysis showing hypergonadotropic hypogonad-
ism because of lack of gonadal function.
Wilm’s Tumor 1 (WT1) is an important regulator of early
gonadal and kidney development [5]. It is expressed earlier in time
than SRY in the urogenital ridge, from which the gonads and
kidneys are derived. All known WT1 isoforms share four C-
terminal zinc fingers which are necessary for DNA/RNA binding.
The two major WT1 isoforms are produced by alternative
splicing, resulting in an insertion (+KTS) or exclusion (-KTS) of
lysine, threonine and serine between zinc fingers three and four.
The –KTS isoform mainly plays a role in transcription, and AMH
transcriptional activation in Sertoli cells [6]. The +KTS isoform is
involved in RNA processing, and in the mouse plays a role in Sry
regulation in vivo [7].
Essential in the process of sex determination is the presence of
the sex determining region on the Y chromosome (SRY) gene
[8,9,10]. SRY mutations residing in the HMG (High Mobility
Group) domains are found in 10–15% of the 46,XY gonadal
dysgenesis cases and affect binding to and bending of DNA or
nuclear transport [11–14]. As a consequence these mutations can
lead to an early error in the process of sex determination
preventing proper formation of a testis. Specific intron 9 splice site
mutations inWT1 resulting in a decreased WT1+KTS isoform are
typically found in FS patients, leading to a diminished expression
of SRY and subsequently SOX9, thereby disturbing testicular
development [15]. Furthermore, knockout mice for the +KTS
isoform showed sex reversal in males [16]. Thus both SRY and
WT1 mutations can cause (complete) sex reversal.
A highly informative marker for the presence of type II GCCs
(i.e. GB, CIS and their invasive counterparts dysgerminoma and
seminoma as well as embryonal carcinoma) is the transcription
factor OCT3/4, also known as POU5F1 [17]. OCT3/4 is
involved in the regulation of pluripotency, is expressed in PGCs
and gonocytes during normal gonadal development, is required for
PGC survival, and is lost after maturation to pre-spermatogonia in
males and oogonia in females [17–20]. In DSD patients OCT3/4
positivity of the germ cells might be due to maturation delay and
not due to malignant transformation. To distinguish between
these, Stem Cell Factor (SCF, also known as KITLG) has been
shown to be informative [21]. GB arises in the context of
granulosa cells, staining positive for FOXL2 and negative for
SOX9 (a Sertoli cell marker), this in contrast to the precursor
lesion arising in a testicular environment, being CIS, in which the
supportive (Sertoli) cells are negative for FOXL2 and stain positive
for SOX9 [22].
Here, we present a unique case with bilateral GB and
dysgerminoma in an adult woman presenting with primary
amenorrhea at the age of 22 years, who was initially diagnosed
with 46,XY gonadal dysgenesis. Mutation analysis identified
a novel missense mutation (c.383A.G, p.Lys128Arg) in the
HMG domain of the SRY, which did not have a significant effect
on transcriptional activation and nuclear import in vitro. Laparos-
copy revealed streak ovaries with GB and dysgerminoma on both
sides. During follow-up the patient developed progressive renal
failure based on focal glomerulosclerosis. Subsequent analysis of
the WT1 gene revealed a splice site exon 9 mutation
(IVS9+5 G.A) resulting in the final diagnosis FS. Sequence
analysis of DNA from five additional FS patients with a proven
WT1 mutation for SRY mutations did not reveal any variants,
indicating that the presence of mutations in both genes in FS
patients is rare. To our knowledge this is the first case describing
a patient with a mutation in both WT1 and SRY, and underlines
the importance of proper diagnosis, especially in patients with an
increased risk for GCC, allowing early diagnosis and treatment,
thus preventing the development of invasive cancer.
Materials and Methods
Tissue Samples
Anonymized tissue samples were collected from our diagnostic
archives and diagnosed according to WHO standards [23] by an
experienced pathologist in gonadal pathology, including GCC
(JWO). Use of tissue samples for scientific reasons was approved by
the Medical Ethical Committee ErasmusMC (MEC 02.981 and
CCR2041). Samples were used according to the ‘‘Code for Proper
Secondary Use of Human Tissue in The Netherlands’’ as
developed by the Dutch Federation of Medical Scientific Societies
(FMWV (Version 2002, updated 2011).
Immunohistochemical Staining
Immunohistochemical staining was performed on formalin fixed
paraffin embedded samples of 3 mm thickness. The antibodies
directed against OCT3/4, c-KIT (CD117), Stem Cell Factor
(SCF), Testis Specific Protein on the Y chromosome (TSPY),
SOX9 and FOXL2 have been described before [21–22]. Briefly,
after deparaffinization and 5 min incubation in 3% H2O2 for
inactivating endogenous peroxidase activity, antigen retrieval was
carried out by heating under pressure of up to 0.9 bar in an
appropriate buffer. After blocking endogenous biotin using the
Avidin/Biotin Blocking Kit (SP-2001; Vector Laboratories,
Burlingame, CA, USA), sections were incubated either overnight
at 4uC (SCF, TSPY) or for 2 h at room temperature (OCT3/4,
SOX9, FOXL2) and detected using the appropriate biotinylated
secondary antibodies and visualized using the avidin–biotin
detection and substrate kits (Vector Laboratories).
SRY Sequencing
Direct sequencing of the SRY gene on peripheral blood DNA
from the patient was performed at the department of clinical
genetics (reference sequence: NM_003140.1). For the additional
samples DNA was isolated from either peripheral blood
lymphocytes (4 patients) or from formalin fixed paraffin embedded
material (from two independent blocks, 1 patient) according to
standard procedures. SRY was PCR amplified, analyzed on a 1%
agarose gel, purified using the Agencourt AMPure XP kit
(Beckman Coulter genomics, Danvers, MA, USA) and Sanger
sequencing was done according to standard procedures.
SRY Transactivation Assay
DNA encoding wild type SRY, mutant SRY and SF1 were
cloned into the pcDNA3 mammalian expression plasmid (Clon-
tech, Mountain View, CA, USA), and sequence verified. To test
for SRY activation of TESCO, in vitro luciferase assays were
performed on a human embryonic kidney carcinoma cell line
(HEK293T, ATCC, CRL-11268). Cells were cultured in DMEM,
High Glucose, GlutaMAX media (Invitrogen, Life Technologies,
Paisley, UK) containing 10% Fetal Bovine Serum, 1% sodium
pyruvate and 1% penicillin-streptomycin. Cultures were grown at
37uC with 5% CO2. Cells were seeded in serum-free media 24
hours prior to transfection in 96-well tissue culture plates at
a density of 30,000 cells per well.
Cells in each well were co-transfected with the reporter
constructs TESCO-E1b-Luc (10 ng) or the empty vector E1b-Luc
(8 ng), together with 40 ng of each of the expression constructs
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pcDNA3-SF1 and either pcDNA3-hSRY (wild-type) or pcDNA3-
SRY-K128R (mutant). The reporter constructs contained the
minimal E1b promoter driving a luciferase gene. pRL-TK-Renilla
(Promega, Madison, WI, USA; 1 ng) was added to each well as an
internal control. pcDNA3 and pUC DNA were added to make up
a total of 100 ng DNA per well, and transfection was performed
with 0.38 ml of FuGENE6 Transfection Reagent (Roche, Basel,
Switzerland) following manufacturer’s instructions. Cells were
lysed 48 h after transfection and firefly and Renilla luciferase
activities were measured using the Dual-Luciferase Reporter Assay
System (Promega).
Six independent assays were performed, each in triplicate.
Firefly luciferase activity (Luc) was normalized against that of
Renilla luciferase (Ren). Luc/Ren readings for TESCO-E1b-Luc
were further normalized against that of E1b-Luc to obtain the
fold change of TESCO activity over that of the empty vector.
Fold change of the mutant SRY-K128R construct was then
normalized against that of wild-type SRY. Data are therefore
represented in the form of mean percentage of wild-type SRY
fold change. Statistical analysis was performed by conducting an
unpaired t-test.
SRY Nuclear Import Assay
pcDNA3-FLAG-SRY plasmid has been described previously
[13]. pcDNA3-FLAG-K128R was created using site-directed
mutagenesis. All constructs were verified by sequencing.
HEK293T cells seeded in 6-well plates were transfected with
2 mg/well of either pcDNA3-FLAG-SRY wild-type or pcDNA3-
FLAG-K128R mutant using Fugene 6 (Roche). After transfection,
immunohistochemistry was carried out using mouse monoclonal
antibody against FLAG tag (1:400). The secondary antibody used
was Alexa 488-conjugated donkey antimouse IgG (1:500, Molec-
ular Probes, Life technologies). DNA was stained with 0.1 mg/ml
of 4’,6-diamidino-2-phenylindole (Molecular Probes, Life technol-
ogies). Image analysis was performed by using NIH ImageJ (public
domain software). Briefly, measurements were taken of the density
of fluorescence from the cytoplasm and the nucleus with the
background fluorescence subtracted from the equation: Fn/c= (n
– bkgdn)/(cp – bkgdcp), where n=nucleus and bkgdn= back-
ground in the nucleus, cp= cytoplasm and bkgdcp= background
in the cytoplasm.
WT1 Mutation Analysis
Mutation analysis was performed at the department of clinical
genetics of the Amsterdam Medical Center. Briefly: Exon 9 of the
WT1 gene (NM_024426, but with the translation initiation codon
starting at c.395), including flanking intronic sequences, was
amplified by PCR followed by direct sequencing using Bigdye v1.1
chemistry and an ABI3100 sequencer (Life Technologies,
Carlsbad, CA, USA). Sequences were analyzed using Codoncode
Aligner (CodonCode Corporation, Dedham, MA, USA).
Results
Patient Clinical History
A phenotypically normal female presented at the outpatient
clinic with primary amenorrhoea at the age of 22. She reported to
have had some vaginal bleeding at the age of 13 and 14 years
which she thought was the start of menarche. This together with
the fact that she grew up in different families was the reason of her
late clinical presentation. Patient history mentioned migraine and
severe asthma for which she was treated with corticosteroids.
Physical examination showed normal female external genitalia,
with Tanner stage III breast development and stage II pubic hair
development. She had a scoliosis and 2.5 cm difference in length
of her legs. Hormonal analyses at the age of 22 and 23 years
revealed low oestradiol: 11 and ,10 pmol/L (normal 100–
1000 pmol/L), testosterone: 1 nmol/L (normal 0.5–3 nmol/L),
high FSH: 215 and 219 IU/L (normal 1–8 IU/L), and high LH:
78 and 75 IU/L (normal 2–8 IU/L) levels, indicating hypergo-
nadotropic hypogonadism. Furthermore an increase in serum
creatinine levels 111–217 umol/L (normal 90 umol/L) was found
over the course of ten months suggestive of impaired kidney
function, although not diagnosed at the time of presentation.
Chromosome analysis on peripheral blood lymphocytes showed
the presence of a 46,XY karyotype, and mutational analysis of the
SRY gene revealed an, at that time, unclassified variant K128R
(c.383 A.G, p.Lys128Arg). Based on these results the patient was
diagnosed with 46,XY gonadal dysgenesis. Laparoscopic exami-
nation showed streak ovaries and a normal, but small, uterus.
Because of the known tumor risk in these patients, both ovaries
were removed during this intervention (for histology, see below).
Two months after gonadectomy the patient visited the
emergency room with complaints of agonizing headache, which
were caused by severe hypertension; her blood pressure was 200/
127 mmHg, with a good response to treatment with Amlodipine.
In addition, blood analyses showed severe renal failure and
additional examinations showed that the progressive renal failure
was due to primary focal glomerulosclerosis. The rapid pro-
gression of kidney failure together with the diagnosis of 46XY
gonadal dysgenesis and bilateral GB and dysgerminoma (for
histology, see below) triggered investigation for a WT1 mutation.
The patient is currently on haemodialysis and awaits kidney
transplantation, which has to be postponed for five years (until
2014) due to the treatment of the GCC.
Histological and Immunohistochemical Analysis
Histological examination of both gonads showed that GB and
dysgerminoma was present in a dysgenetic histological context.
The lesions on both sides were restricted to the gonad. A
representative image of the hematoxylin and eosin (H&E) staining
is shown in Figure 1A. In agreement with this diagnosis, the germ
cells showed positive staining (shown only for the left GB lesion) for
OCT3/4 (Figure 1B), TSPY (Figure 1C) and SCF (Figure 1D). In
addition the supportive cells stained positive for FOXL2
(granulosa cell marker, Figure 1E) and were negative for SOX9
(Sertoli cell marker, Figure 1F). The GB removed from the other
side showed a similar staining pattern for all markers investigated
(data not shown). Both gonads showed multiple micro-calcifica-
tions (microlithiasis), represented in the images of Figure 1.
Mutation Analysis and Functional Analysis of SRY
Direct sequencing of the SRY gene showed the presence of
a single nucleotide change at position 383 (A to G, see Figure 2A),
resulting in a missense substitution (Lysine (K) to Arginine (R)
amino acid change) at position 128 in the SRY protein (hemi-
zygous pattern). A K128R missense mutation in SRY has not been
reported to date. The K128R sequence variant is located within
the HMG domain of SRY next to the C-terminal nuclear import
signal (cNLS) (Figure 2B).
SRY activates SOX9 expression together with SF1 via a testis-
specific enhancer called TESCO, which is located approximately
13 kb upstream of SOX9 [24]. The ability of the SRY K128R
mutant form of SRY to activate SOX9 via TESCO was analyzed.
Results show that the K128R mutation of SRY did not significantly
affect TESCO activity in vitro compared to wild-type SRY
(Figure 2C), although a reduction of about 20% was observed.
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As the K128R substitution is located next to the cNLS, the
effect on nuclear import was also investigated using expression
plasmids encoding wild-type and mutants full-length SRY
transfected in HEK293T cells. The subcellular localization of
SRY was determined 48 h after transfection using indirect
immunofluorescence and quantified using image analysis
(Figure 2D and 2E). Wild type SRY efficiently accumulated in
the nucleus. The mutant K128R also showed a slight reduced but
non-significant difference in nuclear accumulation compared to
the wild type protein, indicating that the K128R mutation does
not affect the nuclear import function of SRY.
Mutation Analysis WT1 and Additional FS Samples
Analyzed
As the patient had 46,XY gonadal dysgenesis together with
renal failure (focal segmental glomerulosclerosis), and GB with
dysgerminoma, without Wilm’s tumor, all pointing to FS, the
WT1 gene was analyzed. Direct sequencing of the WT1 gene
showed a single nucleotide change at the start of intron 9 at the
position +4 (IVS9+4C . T) in a heterozygous state (Figure 2F),
characteristic for FS.
Figure 1. Immunohistochemical staining of the left GB lesion. (A) representative hematoxylin and eosin (HE) staining. The germ cells present
in the GB stain positive for OCT3/4 (B, brown staining), TSPY (C, red staining), and SCF (D, red staining). Supportive cells in the GB stain positive for
FOXL2 (E, brown staining), while SOX9 (F) is negative. All slides are counterstained with hematoxylin. Magnification 100x for all.
doi:10.1371/journal.pone.0040858.g001
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To determine if SRY mutations together with WT1 mutations
were present in other DSD cases with the same clinical
characteristics a review of the literature was done (Tables S1
and S2), showing that this has not been investigated to date.
Therefore an additional five DNA samples from FS patients with
a proven WT1 mutation were analyzed for SRY, showing no
aberrations in SRY in addition to the WT1 mutation.
Discussion
Sex determination and specifically testis differentiation in males
is critically dependent on transcriptional regulation of a selective
number of genes including WT1, SRY, and SOX9 [25–26].
Expression of the Y-chromosome located SRY, above a threshold
and in a critical time window, is crucial in triggering testis
formation. SRY will upregulate SOX9 which will orchestrate the
formation of the pre-Sertoli cells and further regulates testis
development. WT1 is expressed in the gonadal ridges before the
onset of SRY, and plays an important role in testicular as well as
kidney formation. It has been suggested that the WT1+KTS
isoform functions in terminal Sertoli cell differentiation and
homeostasis through the maintenance of a critical level of SRY
and SOX9 expression [15].
SRY mutations play a role in 46,XY sex reversal (46,XY DSD)
and in about 15% of 46,XY gonadal dysgenesis cases mutations
are found [27]. The majority of mutations reside in the HMG
domain, which is involved in the binding and bending of DNA.
Besides these, mutations located in one of the NLSs have been
reported, resulting in a reduced nuclear import of SRY. The
K128R mutation described here does not lead to a statistically
significant reduction in transactivational activity as ascertained by
an in-vitro assay, although a minor reduction (about 20%) was
observed. In addition, although located adjacent to the cNLS of
SRY, the mutation does not result in a significant reduction in
nuclear import of the protein. This suggests that the phenotype of
the patient is not due to a nuclear import defect as has been
observed in other cases [13–14,28]. Although the lysine on
position 128 is conserved between man and mouse, mutation of
lysine on position 128 to arginine does not affect regulation of
SRY subcellular distribution by (de-)acetylation via p300 [29].
Taken together, the results show that the mutation has little effect
on the in vitro transactivation and nuclear import assays available.
Therefore it is unlikely that the SRY K128R mutation has
a significant effect on the (gonadal) phenotype of the patient has,
although a more dramatic effect of the mutation in an in vivo
situation cannot be ruled out.
Reviewing the literature shows that almost all gonadal
dysgenesis cases with a proven SRY mutation (86 cases in total,
Table S1) show a female phenotype (n = 81, 94%). Only a few
cases show ambiguous genitalia (n = 4), and one patient has a male
phenotype with ambiguous genitalia (respectively 5% and 1%). In
a total of 61 cases gonadal histology was analyzed: 18 showed a GB
(30%), one a dysgerminoma (1%) and two GB along with
dysgerminoma (3%). This strongly shows the known increased
GCC risk in these patients (34% in this cohort). Only a limited
number of papers describe the functionality of SRY mutations (20
in total, 23%), and the effects range from completely abolished
DNA binding to no differences in DNA binding when compared
to wild type SRY. Based on these data, no genotype-phenotype
correlation can be gathered (Table S1). In some cases the
mutations described are also present (in mosaic form) in male
family members, with one showing hypospadias and cryptorchi-
dism, one diagnosed with a testicular seminoma, and one without
GCC and a normal male phenotype [30–32] (refs 14, 15 and 54 in
Table S1). Whether this is also the case in the patient described
here, or the mutation arose de novo, cannot be investigated because
family members are not available for analysis (see above).
The patient described here was initially diagnosed as a 46,XY
DSD complete gonadal dysgenesis and a (until now unclassified)
mutation in SRY was found (i.e. Swyer syndrome), associated with
GB and dysgerminoma. However, upon follow-up the diagnosis of
progressive renal failure based on focal segmental glomerulo-
sclerosis, prompted analysis of the WT1 gene. Initially the mild
renal impairment found at presentation was not considered to be
indicative to screen WT1 for mutations.
Mutations in WT1 play a role in 46,XY DSD (i.e. FS, Denys-
Drash syndrome, and WAGR-syndrome), and those found in FS
consist of WT1 intron 9 splice-site mutations. These patients have
complete 46,XY sex reversal, late onset kidney failure (between
10–20 years), focal segmental glomerulosclerosis, streak gonads,
and a high risk for GB, but not Wilm’s tumors [33]. Sequence
analysis of the WT1 gene in the patient described here revealed
a classic FS mutation in the intron 9 splice-site (IVS9+4 C.T).
This ultimately results in the decrease of the +KTS isoform and it
is known that the subsequent reversion in +KTS/2KTS ratio
causes defects in the development of glomerular podocytes and
male sex-determination, ultimately leading to _ephritic syndrome
and male-to-female sex reversal, respectively [33–34]. Careful
review of the literature revealed that this is the first patient
described having both a WT1 as well as a SRY mutation; however
in almost all cases described a mutation screen of both SRY and
WT1 was not performed. Analysis of five additional FS patient
samples with a proven WT1 mutation by conventional Sanger
sequencing of the SRY gene did not reveal any mutations. The
majority of FS patients described in literature are phenotypically
females (n = 48, 96%) and only two phenotypically males are
presented (4%, Table S2). It also underlines the high incidence of
GB and/or dysgerminoma in this patient group; 18 out of 39
patients with described gonadal histology showed GB (46%), in
one patient carcinoma in-situ (CIS) is described, the precursor
Figure 2. Mutational analysis of SRY and WT1. (A) wild type (upper panel, control) and mutated sequence (lower panel, patient) of SRY. (B)
schematic representation of the SRY protein. The K128R mutation resides in the HMG domain, just before the cNLS. (C) In vitro luciferase assays of
SRY-WT (wild-type) and SRY-K128R (mutant) in HEK293T cell line. Cells were co-transfected with TESCO-E1b-Luc, SF1 and WT or mutant SRY to assess
for activation of TESCO. The mean percentages of fold change of luciferase activity of TESCO-E1b-luc over the empty vector, relative to WT SRY levels
from six independent assays (each performed in triplicate) are shown. Error bars represent standard error of the mean (SEM). (D) pcDNA3-FLAG-SRY
wild-type (WT, 2 mg) or pcDNA3-FLAG-SRY mutant (K128R, 2 mg) were transiently transfected into HEK293T cells using Fugene 6. Exogenous SRY (WT
or K128R) expression was detected using a FLAG antibody and a green fluorescent Alexa-488 dye coupled secondary antibody. Nuclei were stained
with 49,6-diamino-2-phenylindole (DAPI). Both wild type and mutant SRY show strong nuclear staining. (E) SRY fluorescence was quantified as
previously described [35]. Nuclear accumulation of SRY (WT or K128R) expressed as fluorescence in the nucleus over that in the cytoplasm (Fn/c) were
background fluorescence has been subtracted. Measurements represent the average of 3 independent transfections. Results are relative to WT
transfected cells (Fn/c given value of 100%). The number of cells analysed is n = 111 (WT) and n= 121 (K128R). Error bars represent the standard error
of mean values. Two-tail t-Test of unpaired sample means was performed between WT transfected cells and mutant transfected cells and showed no
significant differences. P = 0.49. (F) mutated sequence (upper panel, patient) and wild type sequence (lower panel, control) of WT1, showing the
heterozygous +4C.T change.
doi:10.1371/journal.pone.0040858.g002
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lesion of GCC in the testis, and in one patient GB next to CIS is
described. Five patients had an invasive dysgerminoma next to the
GB, one patient is described as having GB and a metastatic tumor,
and one patient is mentioned as having dysgerminoma. In the
other patients with described gonadal histology, the majority show
streak gonads (n = 17, 44%), in one it is described as a dysgenetic
gonad and in one no gonadal tissue could be found. For the other
patients no gonadal histology was analyzed (n= 11).
It has been described that SRY and SOX9 expression can be
diminished in FS [15] and one could speculate that in the case
presented here the effects from reduced SRY expression by
a mutated WT1 were exacerbated by the presence of the SRY
K128R mutation, although a reduced SRY function could not be
shown conclusively in vitro. This situation may have contributed to
the maldevelopment of the gonads, thereby creating the micro-
environment in which embryonic germ cells can survive, and are
prone to become malignant. However, screening an additional five
FS patients with a proven WT1 mutation did not reveal any
sequence variants in SRY. Although this is a limited series of these
unique cases, it indicates that presence of SRY mutations in FS is
rare.
To our knowledge this is the first patient described with
a mutation in SRY together with a classical FS WT1 mutation, and
thus seems to be a rare condition. Nonetheless, in this patient an
optimal diagnosis could have been made, if a screening for WT1
mutation was performed at an earlier time point. The patient is
currently on haemodialysis and awaits kidney transplantation,
which has to be postponed for five years (until 2014) due to the
GCC in her history. This case clearly demonstrates the significant
role of proper diagnosis of the variants of DSD, especially in those
with an increased risk for GCC, allowing early diagnosis and
treatment, thus preventing the development of invasive cancer.
The presence and type of WT1 mutation has major consequences
for the patient. We therefore suggest that WT1 mutation screening
should be performed in all patients with 46,XY gonadal
dysgenesis, especially in case of an unclassified SRY variant, and
not vice versa. In addition, careful evaluation of kidney function at
early stage is recommended in these patients.
Supporting Information
Table S1 SRY mutation literature overview. NA.: not
available, GB: gonadoblastoma, DG: dysgerminoma, SE: semi-
noma, YST: yolk sac tumor, OT: ovotestis, S: streak, DS:
dysgenetic testis, T: testis, ov st: ovarian stroma, GD: gonadal
dysgenesis. POF: Premature Ovarian Failure.
(XLS)
Table S2 WT1mutation literature overview. GB: gonado-
blastoma, CIS: carcinoma in situ, DG: dysgerminoma, d.g.:
dysgenetic gonad, S: streak, NGT: no gonadal tissue, NA.: not
available, GD: gonadal dysgenesis, FSGS: focal segmental
glomerulosclerosis, LC: leydig cell.
(XLS)
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